Page 16 - Read Online

Page 12 Fracaro et al. Neuroimmunol Neuroinflammation 2020;7:1-12 I http://dx.doi.org/10.20517/2347-8659.2019.009

Suppl 1:S79-90.
67. Mendonça MVP, Larocca TF, de Freitas Souza BS, Villarreal CF, Silva LFM, et al. Safety and neurological assessments after
autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther
2014;5:126.
68. Vaquero J, Zurita M, Rico MA, Bonilla C, Aguayo C, et al. Repeated subarachnoid administrations of autologous mesenchymal
stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy
2017;19:349-59.
69. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H. Clinical safety and primary efficacy of bone marrow
mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012;114:935-9.
70. Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord
injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant 2009;7:241-8.
71. Shin JC, Kim KN, Yoo J, Kim IS, Yun S, et al. Clinical trial of human fetal brain-derived neural stem/progenitor cell transplantation in
patients with traumatic cervical spinal cord injury. Neural Plast 2015;2015:630932.
72. Oh SK, Choi KH, Yoo JY, Kim DY, Kim SJ, et al. A phase III clinical trial showing limited efficacy of autologous mesenchymal stem
cell therapy for spinal cord injury. Neurosurgery 2016;78:436-47.